Prostate cancer: An enzalutamide antiandrogen withdrawal syndrome

摘要

New research has shown, for the first time, that discontinuation of enzalutamide treatment elicits an antiandrogen withdrawal syndrome (AAWS) response in a small minority of patients with metastatic castration-resistant prostate cancer (mCRPC). Prostate cancer is initially sensitive to androgen deprivation therapy (ADT), but ultimately progresses to CRPC. Although CRPC is resistant to ADT, androgen signalling persists, and antiandrogens can further delay disease progression. Resistance to antiandrogens is thought to develop via mutations in the androgen receptor that cause antiandrogens to act as partial receptor agonists.